Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old

Clicks: 468
ID: 117149
1994
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #14 of 46 articles by views in the pediatric infectious disease journal

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
A subunit vaccine for respiratory syncytial virus (RSV) consisting of purified fusion glycoprotein (designated PFP-1) was tested in children 24 to 48 months old. Two doses of 20 micrograms (n = 13) and 50 micrograms (n = 10) were compared with a saline (n = 24) placebo control group. Local and syste …
Reference Key
pr1994thesafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Paradiso PR;Hildreth SW;Hogerman DA;Speelman DJ;Lewin EB;Oren J;Smith DH;;
Journal the pediatric infectious disease journal
Year 1994
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.